Augmentation of Clozapine with Aripiprazole in Severe Psychotic Bipolar and Schizoaffective Disorders: a Pilot Study

Overview

Journal Clin Pract Epidemiol Ment Health

Publisher Bentham Open

Specialty Psychiatry

Date 2010 Jul 22

PMID 20648219

Citations 6

Authors

Alessandra Benedetti

Antonello Di Paolo

Marianna Lastella

Francesco Casamassima

Chiara Candiracci

Antonella Litta

Laura Ciofi

Romano Danesi

Lorenzo Lattanzi

Mario Del Tacca

Giovanni Battista Cassano

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the efficacy and safety of the augmentation of clozapine with aripiprazole in patients with treatment-resistant schizoaffective and psychotic bipolar disorders in a retrospective manner. Pharmacodynamic and pharmacokinetic interactions between the two drugs were also investigated.

Patients: Three men and 4 women (median age 36 and 40 years, respectively) who had mean scores at BPRS and CGI-Severity of 59.1+/-12.0 and 5.4+/-0.5, respectively, were treated with clozapine (mean dose 292.9+/-220.7 mg/day). Patients received an adjunctive treatment with aripiprazole (mean dose 6.8 +/- 3.7 mg/day). Clozapine, norclozapine and aripiprazole plasma levels were measured by means of a high performance liquid chromatograpy with UV detection.

Results: Total scores at BPRS decreased significantly (from 59.1+/-12.0 to 51.1+/-15.6, p=0.007) after aripirazole augmentation. In particular, the factors "thought disorder" (from 10.4+/-4.4 to 9.0+/-4.5, p=.047) and "anergia" (from 10.0+/-2.7 to 8.0+/-2.4, p=.018) significantly improved. Concomitant administration of aripiprazole and clozapine did not result in an increase in side effects over the period of treatment. Dose-normalized plasma levels of both clozapine and norclozapine and the clozapine/norclozapine metabolic ratio in all patients did not vary as well.

Conclusion: The augmentation of clozapine with aripirazole was safe and effective in severe psychotic schizoaffective and bipolar disorders which failed to respond to atypical antipsychotics. A possible pharmacokinetic interaction between clozapine and aripiprazole does not account for the improved clinical benefit obtained after aripiprazole augmentation.

Citing Articles

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?.

Vasiliu O Front Psychiatry. 2022; 13:1069432.

PMID: 36523870 PMC: 9744942. DOI: 10.3389/fpsyt.2022.1069432.

Clozapine-induced stuttering in the absence of known risk factors: a case report.

Jaguga F J Med Case Rep. 2021; 15(1):174.

PMID: 33863375 PMC: 8052697. DOI: 10.1186/s13256-021-02803-8.

The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.

Fountoulakis K, Yatham L, Grunze H, Vieta E, Young A, Blier P Int J Neuropsychopharmacol. 2019; 23(4):230-256.

PMID: 31802122 PMC: 7177170. DOI: 10.1093/ijnp/pyz064.

Pharmacological Approaches for Treatment-resistant Bipolar Disorder.

Poon S, Sim K, Baldessarini R Curr Neuropharmacol. 2015; 13(5):592-604.

PMID: 26467409 PMC: 4761631. DOI: 10.2174/1570159x13666150630171954.

Ziprasidone as adjunctive therapy in severe bipolar patients treated with clozapine.

Bartolommei N, Casamassima F, Pensabene L, Luchini F, Benvenuti A, Di Paolo A ISRN Psychiatry. 2014; 2014:904829.

PMID: 25006524 PMC: 4003829. DOI: 10.1155/2014/904829.

References

Hamamura T, Harada T . Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology (Berl). 2007; 191(3):741-3. DOI: 10.1007/s00213-006-0654-2. View

Abu-Tair F, Kopitz J, Bergemann N . Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol. 2006; 26(6):669-71. DOI: 10.1097/01.jcp.0000246206.65411.f5. View

Gao K, Kemp D, Ganocy S, Gajwani P, Xia G, Calabrese J . Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol. 2008; 28(2):203-9. PMC: 3489178. DOI: 10.1097/JCP.0b013e318166c4d5. View

Ziegenbein M, Sieberer M, Calliess I, Kropp S . Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust N Z J Psychiatry. 2005; 39(9):840-1. DOI: 10.1111/j.1440-1614.2005.01688_2.x. View

Hirose T, Kikuchi T . Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005; 52 Suppl:284-90. DOI: 10.2152/jmi.52.284. View

Rocha F, Hara C . Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6):1167-9. DOI: 10.1016/j.pnpbp.2006.03.024. View

. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159(4 Suppl):1-50. View

Henderson D, Kunkel L, Nguyen D, Borba C, Daley T, Louie P . An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006; 113(2):142-7. DOI: 10.1111/j.1600-0447.2005.00612.x. View

Chang J, Ahn Y, Park H, Lee K, Kim S, Kang U . Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69(5):720-31. DOI: 10.4088/jcp.v69n0505. View

10.

Englisch S, Zink M . Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6):1386-92. DOI: 10.1016/j.pnpbp.2008.02.010. View

11.

Nose M, Accordini S, Artioli P, Barale F, Barbui C, Beneduce R . Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials. 2009; 10:31. PMC: 2689216. DOI: 10.1186/1745-6215-10-31. View

12.

Grunder G, Carlsson A, Wong D . Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry. 2003; 60(10):974-7. DOI: 10.1001/archpsyc.60.10.974. View

13.

Kirschbaum K, Muller M, Zernig G, Saria A, Mobascher A, Malevani J . Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem. 2005; 51(9):1718-21. DOI: 10.1373/clinchem.2005.049809. View

14.

Pacher P, Kecskemeti V . Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des. 2004; 10(20):2463-75. PMC: 2493295. DOI: 10.2174/1381612043383872. View

15.

Mitsonis C, Dimopoulos N, Mitropoulos P, Kararizou E, Katsa A, Tsakiris F . Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 31(2):373-7. DOI: 10.1016/j.pnpbp.2006.09.015. View

16.

Karunakaran K, Tungaraza T, Harborne G . Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. J Psychopharmacol. 2006; 21(4):453-6. DOI: 10.1177/0269881106068289. View

17.

Remington G, Saha A, Chong S, Shammi C . Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs. 2005; 19(10):843-72. DOI: 10.2165/00023210-200519100-00004. View

18.

Kapur S, Seeman P . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001; 158(3):360-9. DOI: 10.1176/appi.ajp.158.3.360. View

19.

Ciapparelli A, DellOsso L, di Poggio A, Carmassi C, Cecconi D, Fenzi M . Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry. 2003; 64(4):451-8. DOI: 10.4088/jcp.v64n0416. View

20.

Advokat C . Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain. Essent Psychopharmacol. 2005; 6(2):73-90. View